Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy

Inclusion Criteria: * Severe non-proliferative diabetic retinopathy or retinal neovascularization secondary to diabetic retinopathy meeting DRS criteria for PRP laser * ETDRS (Early treatment of Diabetic Retinopathy Study) eye score of at least 34-73 letters (at 2 meters) (20/20 to 20/320) for study eye and 20/800 in non-study eye * Clinical evidence of macular microantiopathy in the study eye (lipid or retinal thickness is acceptable) * No other ocular disease that could be responsible for decreased vision, macular edema or could limit macular imaging Exclusion Criteria: * Individuals with retinal neovascularization from causes other than diabetic retinopathy * Any intraocular surgery within 2 months or Yag capsulotomy within 1 month in the study eye * Prior retinal or vitreous surgery (including posterior segment vitrectomy or scleral buckling) * Medical conditions requiring the use of mineral supplements (copper in particular) * Individuals with anemia * Individuals with mental or physical disabilities that prevent accurate vision testing * History of treatment of PDR by PRP * Active hepatitis, clinically significant liver disease or any evidence of renal failure. * Stroke or myocardial infarction within preceding 6 months or ventricular tachycardia under treatment * History of severe cardiac disease or unstable angina * Subjects who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks * Subjects who are a poor medical …